Scale with measuring tape on top

©pixelshot via Canva.com

Novo Nordisk Announces $6B Investment in Ozempic, Wegovy Amid Shortages

May 3, 2024

Lucille Barilla

Novo Nordisk, the maker of popular drugs for weight loss, including Ozempic and Wegovy, is investing $6 billion to meet the increased demand for these drugs amid shortages.

Negelle Morris, senior vice president and head of U.S. cardiometabolic sales at Novo Nordisk Inc., spoke to Good Morning America about the topic. Although Morris said the company is investing money into these products, there will still likely be delays in bringing the in-demand drugs to the market.

“It’s not like a light switch,” Morris said in an interview with Good Morning America. “The strategy is to be very mindful and thoughtful about the amount of the lower doses that we’re putting into the market, and I think that over time, the investments that we’re making in manufacturing capabilities will ensure that over time we’re able to meet that demand.”


Reportedly, the smaller size shots of the drugs are the most in-demand from consumers — these range from 0.25 milligram to 1 milligram, reports The Food and Drug Administration. However, the FDA reveals that some shots are still available. These include Wegovy 1.7mg, 2.4mg, Ozempic 1.34mg, 2.68mg, and 0.68mg. Ozempic is currently available in all dosages, according to the FDA.

Despite the decrease in the smaller shots, Novo Nordisk said in a statement to ABC News the company has enough of its Wegovy product on the market to start 25,000 patients on Wegovy each week.

Semaglutide, the main ingredient in Ozempic and Wegovy, is FDA-approved for weight loss. The Novomedlink website markets Wegovy as a weight loss drug that should be used in combination with a reduced calorie diet and increased physical activity to help with obesity. 


Ozempic was initially created for use by diabetes to improve blood sugar in those with type 2 diabetes and to reduce the risk of major cardiovascular events. It also suggests keeping a well-balanced diet for the medication to be effective. Finally, Rybelsus is a once-a-day medication that produces the same results as Wegovy and Ozempic. However, it is a pill rather than an injectable.

Recent News

Massive Data Breach Hits Ticketmaster, Affecting 560 Million Customers

Ticketmaster has fallen victim to a significant cyber-attack, potentially compromising the data of up to 560 million customers. The breach was confirmed by Ticketmaster’s parent company, Live Nation, which revealed that a notorious hacking group, ShinyHunters, is behind the attack. The hackers are demanding a ransom of approximately £400,000 to prevent the data from being sold on the dark web.

Toyota Recalls 100,000+ Tundra and Lexus LX SUVs Over Engine Debris Issue

Toyota has announced a recall for over 100,000 Tundra pickups and Lexus LX SUVs in North America due to potential engine issues caused by machining debris. This recall affects certain 2022-2023 models of the Tundra and LX, which are equipped with the new V6 twin-turbo engine. The V6 twin-turbo engine has faced considerable scrutiny regarding its reliability, especially when compared to the previous naturally aspirated V8 engines.

Wordle and Worldle Battle Over Names

A legal dispute has erupted between the wildly popular word game Wordle and the lesser-known geography game Worldle, centering on the similarity of their names. Wordle, which was developed by Josh Wardle in 2021 and later acquired by the New York Times in 2022 for a substantial sum, has gained immense popularity. In this game, players have six attempts to guess a five-letter word. 

FDA Issues Recall for Crecelac Goat Milk Infant Formula

The U.S. Food and Drug Administration (FDA) has issued a safety alert regarding Crecelac Goat Milk Infant Formula and other infant formula products imported and distributed by Dairy Manufacturers Inc. The alert highlights Cronobacter contamination concerns with Crecelac Infant Powdered Goat Milk Infant Formula. Although Dairy Manufacturers Inc. initiated a recall on May 24, 2024, due to non-compliance with FDA regulations, new findings of Cronobacter contamination have prompted further action.